Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLIS: H01 in Adults With Interstitial Lung Disease
NCT06325696Phase 2Recruiting
- Sponsor
- National Institute of Environmental Health Sciences
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hymecromone in interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), sponsored by National Institute of Environmental Health Sciences. Started May 2025; status: recruiting.
02
Drugs
hymecromone
03
Conditions
interstitial lung disease (ILD)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06325696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06325696.